Baidu
map

利比里亚再现埃博拉病例,10岁男童确认感染

2015-11-23 佚名 新华网

世界卫生组织助理总干事布鲁斯·艾尔沃德20日在日内瓦表示,利比里亚19日再次报告出现埃博拉确诊病例,他呼吁在当前埃博拉疫情应对的第三阶段加强预防、监测与应对新病例的能力。 世卫组织此前于5月9日和9月3日两次宣布利比里亚埃博拉疫情结束。艾尔沃德当日在日内瓦万国宫举行的记者会上表示,新出现的埃博拉患者为利比里亚首都蒙罗维亚的一名10岁男童,该病人于本月14日出现身体不适后入院治疗,19日正式被确认

世界卫生组织助理总干事布鲁斯·艾尔沃德20日在日内瓦表示,利比里亚19日再次报告出现埃博拉确诊病例,他呼吁在当前埃博拉疫情应对的第三阶段加强预防、监测与应对新病例的能力。

世卫组织此前于5月9日和9月3日两次宣布利比里亚埃博拉疫情结束。艾尔沃德当日在日内瓦万国宫举行的记者会上表示,新出现的埃博拉患者为利比里亚首都蒙罗维亚的一名10岁男童,该病人于本月14日出现身体不适后入院治疗,19日正式被确认感染埃博拉病毒。该男童并未与任何已知的埃博拉康复者有过接触或旅行史。

艾尔沃德表示,针对新增病例的病理学调查已迅速展开,他估计该男童是被康复患者体内残存的病毒感染。他援引上月发布的一份报告指出,埃博拉病毒在幸存者精液中最长可存活9个月,患者康复3个月后精液中埃博拉病毒检测呈阳性的概率为90%,康复6个月后降至50%,康复9个月后降为20%。

他表示,康复者体内残存的病毒可能与病例再次出现存在关联,从历史上看,半数曾暴发埃博拉疫情的国家在疫情结束两年内再次报告了新增病例。

艾尔沃德指出,当前疫情应对第三阶段的主要目标是阻断现有及残存的病毒传播链,确保西非三国具备应对病毒再次出现的能力。西非三国在此阶段应做好康复后工作,让康复患者了解病毒可继续存活的情况,提倡安全性行为,并确保他们获得持续的医疗护理及心理和社会支持;确保三国在2016年维持高度监测状态,保证在新病例报告后48小时内快速应对。

埃博拉疫情应对的第三阶段从今年10月1日持续至明年3月末,艾尔沃德表示该阶段的资金缺口为1.23亿美元。不过考虑到几内亚已有21天未报告与最初疫情相关的埃博拉病例,塞拉利昂日前也已宣布疫情结束,艾尔沃德表示对2016年结束埃博拉疫情充满信心。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=159141, encodeId=153015914197, content=疫苗不是被研究出来了吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:50:24 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159140, encodeId=353015914066, content=怎么办, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:49:51 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159139, encodeId=e722159139f1, content=死灰复燃, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:49:33 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119318, encodeId=3fc811931896, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 15:02:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119317, encodeId=d05c11931e97, content=谢谢分享,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 15:01:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650343, encodeId=e834165034382, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Wed Oct 19 11:32:00 CST 2016, time=2016-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54723, encodeId=a5c954e23ad, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 20:09:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
    2016-11-30 博雷

    疫苗不是被研究出来了吗

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=159141, encodeId=153015914197, content=疫苗不是被研究出来了吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:50:24 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159140, encodeId=353015914066, content=怎么办, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:49:51 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159139, encodeId=e722159139f1, content=死灰复燃, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:49:33 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119318, encodeId=3fc811931896, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 15:02:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119317, encodeId=d05c11931e97, content=谢谢分享,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 15:01:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650343, encodeId=e834165034382, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Wed Oct 19 11:32:00 CST 2016, time=2016-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54723, encodeId=a5c954e23ad, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 20:09:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
    2016-11-30 博雷

    怎么办

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=159141, encodeId=153015914197, content=疫苗不是被研究出来了吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:50:24 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159140, encodeId=353015914066, content=怎么办, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:49:51 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159139, encodeId=e722159139f1, content=死灰复燃, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:49:33 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119318, encodeId=3fc811931896, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 15:02:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119317, encodeId=d05c11931e97, content=谢谢分享,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 15:01:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650343, encodeId=e834165034382, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Wed Oct 19 11:32:00 CST 2016, time=2016-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54723, encodeId=a5c954e23ad, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 20:09:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
    2016-11-30 博雷

    死灰复燃

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=159141, encodeId=153015914197, content=疫苗不是被研究出来了吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:50:24 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159140, encodeId=353015914066, content=怎么办, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:49:51 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159139, encodeId=e722159139f1, content=死灰复燃, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:49:33 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119318, encodeId=3fc811931896, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 15:02:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119317, encodeId=d05c11931e97, content=谢谢分享,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 15:01:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650343, encodeId=e834165034382, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Wed Oct 19 11:32:00 CST 2016, time=2016-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54723, encodeId=a5c954e23ad, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 20:09:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
    2016-09-10 医路开来

    学习啦,,,

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=159141, encodeId=153015914197, content=疫苗不是被研究出来了吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:50:24 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159140, encodeId=353015914066, content=怎么办, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:49:51 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159139, encodeId=e722159139f1, content=死灰复燃, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:49:33 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119318, encodeId=3fc811931896, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 15:02:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119317, encodeId=d05c11931e97, content=谢谢分享,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 15:01:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650343, encodeId=e834165034382, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Wed Oct 19 11:32:00 CST 2016, time=2016-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54723, encodeId=a5c954e23ad, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 20:09:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
    2016-09-10 医路开来

    谢谢分享,,

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=159141, encodeId=153015914197, content=疫苗不是被研究出来了吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:50:24 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159140, encodeId=353015914066, content=怎么办, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:49:51 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159139, encodeId=e722159139f1, content=死灰复燃, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:49:33 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119318, encodeId=3fc811931896, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 15:02:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119317, encodeId=d05c11931e97, content=谢谢分享,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 15:01:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650343, encodeId=e834165034382, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Wed Oct 19 11:32:00 CST 2016, time=2016-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54723, encodeId=a5c954e23ad, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 20:09:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=159141, encodeId=153015914197, content=疫苗不是被研究出来了吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:50:24 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159140, encodeId=353015914066, content=怎么办, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:49:51 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159139, encodeId=e722159139f1, content=死灰复燃, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:49:33 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119318, encodeId=3fc811931896, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 15:02:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119317, encodeId=d05c11931e97, content=谢谢分享,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 15:01:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650343, encodeId=e834165034382, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Wed Oct 19 11:32:00 CST 2016, time=2016-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54723, encodeId=a5c954e23ad, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 20:09:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
    2016-01-08 andruhn

    好东西,值得分享,学习了!

    0

相关资讯

Nature Commun:降胆固醇药物能够用于治疗急性埃博拉吗?

海德堡大学膜研究生化学家在其研究过程中获得对于埃博拉病毒细胞致毒作用的新发现。通过采用生物化学和细胞生物学方法,他们揭示了埃博拉病毒糖蛋白及其在调控细胞毒性中的分子机制。Felix Wieland教授和他在生物化学中心(BZH)的研究团队发现病毒糖蛋白与细胞胆固醇之间可发生作用,该现象使得在研究中进行特定降胆固醇药物的使用。研究人员称在细胞培养过程中成功的抑制了细胞损伤。该成果已发表在Nature

NEJM:埃博拉病毒性传播案例及启示

埃博拉病毒(EBOV)会导致人类和非人类灵长类动物出现严重的出血热,并且埃博拉(EVD) 死亡率很高,在新的地理区域持续出现新案例,包括爆发数目最多的区域——非洲西部。WHO数据显示,在几内亚、利比里亚和塞拉利昂有超过 28,000例确认或可疑EVD病人,并且有超过11,000 人因该病死亡。美国陆军与利比里亚生物医学研究所(LIBR)的科学家合作通过基因分析,确诊了一例通过性传播的可疑EVD。近

Lancet:埃博拉病毒影响了对疟疾病例的管理

正在非洲西部蔓延的埃博拉病毒疫情已经破坏了受影响国家的整个卫生保健系统。由于埃博拉病毒感染与疟疾的症状有一定的重叠性,所以对于疟疾提供的治疗方法对目前埃博拉疾病疫情的间接影响十分敏感。因此研究人员在埃博拉疫情蔓延的背景下以疟疾病例的管理为典型进而据此对埃博拉疾病疫情的影响进行记录。    2014年12月,研究人员对几内亚的公共卫生场所做了一次具有代表性的调查。挑选了

英国护士Pauline Cafferkey再次战胜埃博拉

世卫组织总干事Bruce Aylward认为,卓越的领导、迅速采取应对措施、并不断创新治疗方案是消灭埃博拉病毒的关键。

盘点:Nature杂志8月亮点研究看过来!

时间定格在8月底,不知不觉又到了亮点研究盘点的时间,本期小编为大家带来8月份Nature杂志众多亮点研究盘点。【1】埃博拉病毒造成的新疫情 当前由埃博拉病毒所造成的疫情正在西非蔓延。在7月22日之前的一个星期,国际卫生组织报告说,在几内亚有22个已证实的病例,在塞拉利昂有4个,在利比里亚没有——5月9日该疫情在利比里亚已宣告“结束”。本期Nature杂志的特写文章总结了在应对本次疫情中

Nature:解读100%有效的埃博拉疫苗研制成功如何重塑临床试验

2013年12月西非爆发埃博拉病毒,引发埃博拉有史以来规模最大的流行,并且当时没有安全有效的疫苗或药物。短短20个月后,7月31日柳叶刀杂志刊登了在几内亚进行的初步实验成果,新研发出的疫苗能针对感染给予几乎100%全面的保护。Nature杂志着眼于试验的初步成功,综合分析了新疫苗将会对已经造成超过11000人死亡的疫情产生的影响以及在疫情爆发中如何进行未来的临床试验。 该疫苗是怎么来的?

Baidu
map
Baidu
map
Baidu
map